Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Ampersand Capital Partners provides growth equity to expand business
November 20, 2015
By: Tim Wright
Editor-in-Chief, Contract Pharma
Florida Biologix, a contract development and manufacturing organization (CDMO) focused on complex biological products, has spun-off from the University of Florida (UF) with financial backing from Ampersand Capital Partners. Ampersand’s investment will be used to further expand the company’s manufacturing capabilities in the areas of gene and cell therapies. Florida Biologix was established in 2006 as a component of the UF Center of Excellence for Regenerative Health Biotechnology with a mission to provide drug-development services to the biotechnology industry. The State of Florida, the University of Florida, and the U.S. Department of Commerce Economic Development Administration provided the center with seed funding as part of Florida’s effort to grow its biotechnology industry. Florida Biologix will continue to operate out of its existing Progress Park facility, and will also lease UF facilities on Innovation Drive in Alachua, FL. Most of the more than 100 UF Florida Biologix employees will continue with the business, including founding director Richard Snyder and all of the senior scientific team. In addition new members have been added to the senior team. “Florida Biologix is a leading company in its field and given the exciting developments within the complex biologics market this is an excellent time for UF to pass the stewardship to the private sector,” said David Anderson, partner, Ampersand. In connection with Ampersand’s investment, Tim Martin was recruited to serve as chief executive officer of Florida Biologix. “I am very excited to join Florida Biologix. The company has extensive expertise in a wide array of biopharmaceutical products with an emphasis on the emerging areas of gene and cell therapy,” said Mr. Martin. “After working with Ampersand to survey the contract development and manufacturing services industry focused on complex biologics, we determined that Florida Biologix occupies a unique position in this space.” David Day, assistant vice president and director of UF’s office of technology licensing, said, “What started as a division of a UF center is now a flourishing private company with more than 100 employees delivering cutting edge science to some of the most innovative biotechnology companies in the world.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !